PDGFRB Amplification is an inclusion criterion in 5 clinical trials for non-small cell lung carcinoma, of which 3 are open and 2 are closed. Of the trials that contain PDGFRB Amplification and non-small cell lung carcinoma as inclusion criteria, 5 are phase 2 (3 open) [5].

PDGFRB Amplification is an inclusion criterion in 2 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 2 are open and 0 are closed. Of the trials that contain PDGFRB Amplification and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 2 are phase 2 (2 open) [5].

PDGFRB Amplification is an inclusion criterion in 2 clinical trials for cancer, of which 1 is open and 1 is closed. Of the trials that contain PDGFRB Amplification and cancer as inclusion criteria, 2 are phase 2 (1 open) [5].

PDGFRB Amplification is an inclusion criterion in 2 clinical trials for pancreatic carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PDGFRB Amplification and pancreatic carcinoma as inclusion criteria, 2 are phase 2 (2 open) [5].

PDGFRB Amplification is an inclusion criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB Amplification and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRB Amplification is an inclusion criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB Amplification and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRB Amplification is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB Amplification and breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRB Amplification is an inclusion criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB Amplification and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRB Amplification is an inclusion criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB Amplification and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRB Amplification is an inclusion criterion in 1 clinical trial for colorectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB Amplification and colorectal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRB Amplification is an inclusion criterion in 1 clinical trial for diffuse intrinsic pontine glioma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB Amplification and diffuse intrinsic pontine glioma as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRB Amplification is an inclusion criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB Amplification and esophageal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRB Amplification is an inclusion criterion in 1 clinical trial for esophageal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB Amplification and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRB Amplification is an inclusion criterion in 1 clinical trial for gallbladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB Amplification and gallbladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRB Amplification is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB Amplification and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRB Amplification is an inclusion criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB Amplification and gastric carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRB Amplification is an inclusion criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB Amplification and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRB Amplification is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB Amplification and head and neck carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRB Amplification is an inclusion criterion in 1 clinical trial for hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB Amplification and hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRB Amplification is an inclusion criterion in 1 clinical trial for lip and oral cavity carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB Amplification and lip and oral cavity carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRB Amplification is an inclusion criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB Amplification and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRB Amplification is an inclusion criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB Amplification and malignant glioma as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRB Amplification is an inclusion criterion in 1 clinical trial for malignant hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB Amplification and malignant hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRB Amplification is an inclusion criterion in 1 clinical trial for malignant laryngeal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB Amplification and malignant laryngeal neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRB Amplification is an inclusion criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB Amplification and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRB Amplification is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB Amplification and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRB Amplification is an inclusion criterion in 1 clinical trial for malignant uterine neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB Amplification and malignant uterine neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRB Amplification is an inclusion criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB Amplification and melanoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRB Amplification is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB Amplification and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRB Amplification is an inclusion criterion in 1 clinical trial for nasal cavity and paranasal sinus carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB Amplification and nasal cavity and paranasal sinus carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRB Amplification is an inclusion criterion in 1 clinical trial for nasopharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB Amplification and nasopharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRB Amplification is an inclusion criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB Amplification and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRB Amplification is an inclusion criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB Amplification and ovarian carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRB Amplification is an inclusion criterion in 1 clinical trial for small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PDGFRB Amplification and small cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) [5].

PDGFRB Amplification is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB Amplification and soft tissue sarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRB Amplification is an inclusion criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB Amplification and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRB Amplification is an inclusion criterion in 1 clinical trial for WHO grade II glioma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB Amplification and WHO grade II glioma as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRB Amplification is an inclusion criterion in 1 clinical trial for WHO grade III glioma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB Amplification and WHO grade III glioma as inclusion criteria, 1 is phase 2 (1 open) [5].